The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab

Published:2024-01-08 Issue:3 Volume:65 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Honigman Anthony¹^ORCID,Oo Hnin P.¹^ORCID,Macdonell Richard²³^ORCID,Kern Johannes S.¹⁴⁵⁶^ORCID

Affiliation:

1. Dermatology Department The Royal Melbourne Hospital Parkville Victoria Australia

2. Department of Neurology Austin Health Heidelberg Victoria Australia

3. Faculty of Medicine, Dentistry and Health Sciences, Austin Health The University of Melbourne Melbourne Victoria Australia

4. Faculty of Medicine, Dentistry and Health Services, The Royal Melbourne Hospital The University of Melbourne Melbourne Victoria Australia

5. Department of Dermatology Alfred Health Melbourne Victoria Australia

6. Department of Medicine, Central Clinical School Monash University Melbourne Australia

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14205

Reference5 articles.

1. Fremanezumab for the Preventive Treatment of Chronic Migraine

2. Inflammatory complications of CGRP monoclonal antibodies: a case series

3. Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

4. Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP